Fig. 1.

Anti-PDL1 clone HDX3 has a similar staining profile as approved anti-PD-L1 clones (22C3, SP263). (A) 206 whole-slide samples from NSCLC patients were analysed for PD-L1 TPS: (Blue dot) HDX3, (orange dot) SP263, (Cyan dot) 22C3. (B) Correlation between the PD-L1 clones HDX3, 22C3 and SP263 for the quantification of PD-L1 TPS. (C) Representative images of PD-L1 staining of tissue sections from 3 different patients. (D) Contingency tables showing the agreement between HDX3 and 22C3 or SP263 for the assessment of PD-L1 TPS. (E) Evaluation of the impact of batch-to-batch variability for HDX3/PD-L1 TPS across 4 levels (L0–L3): level 0: non-stained tumour; level 1: weakly stained tumour; level 2: moderately stained tumour; and level 3: strongly stained tumour.